

# Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)

Technology appraisal guidance

Published: 19 November 2025

[www.nice.org.uk/guidance/ta1112](https://www.nice.org.uk/guidance/ta1112)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because Daiichi Sankyo UK has confirmed that it does not intend to make an evidence submission for the appraisal. Daiichi Sankyo UK considers that the technology is unlikely to be a cost-effective use of NHS resources at this time.

## Information

If NHS organisations wish to consider trastuzumab deruxtecan for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-7326-2